[From marker expression to individual therapy of patients with bladder cancer].
Urothelial carcinoma of the bladder is a tumor entity with a heterogenous clinical course. At one end of the spectrum, patients are treated for low-grade carcinomas, which are likely to reccur but show low rates of tumor progression. At the other end, patients suffer from noninvasive or early invasive high-grade carcinomas. In these cases, risk-adapted treatment decisions are more complicated. The following article gives an overview of research activities on bladder cancer with the aim to individualize treatment of patients with bladder cancer.
Vom Dorp
F
F
Klinik und Poliklinik für Urologie, Kinderurologie und urologische Onkologie, Universitätsklinikum, Essen, Deutschland. frankvomDorp@web.de
Börgermann
C
C
Jäger
T
T
Becker
M
M
Schmid
K W
KW
Rübben
H
H
D014408:Biomarkers, Tumor / Q000032:analysis*; D002295:Carcinoma, Transitional Cell / Q000473:pathology* / Q000628:therapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D006801:Humans; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local / Q000473:pathology / Q000628:therapy; D009367:Neoplasm Staging; D011379:Prognosis; D012106:Research; D046888:Tissue Array Analysis; D001743:Urinary Bladder / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology* / Q000628:therapy
D014408:Biomarkers, Tumor